CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
2017 ◽
Vol 18
(7)
◽
pp. 917-928
◽
Keyword(s):
Phase 3
◽
Keyword(s):